Current frontline therapies for patients with type 2 diabetes include glucagon-like peptide-1 (GLP-1) mimetics that not only harness the insulin-stimulating and glucagonostatic properties of the endogenous hormone, but also lower body weight through induction of satiety (1). The gene discussed is GCG; the disease is type 2 diabetes mellitus.